Compare ESP & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ESP | MOLN |
|---|---|---|
| Founded | 1928 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.4M | 158.9M |
| IPO Year | 1995 | 2021 |
| Metric | ESP | MOLN |
|---|---|---|
| Price | $56.40 | $4.05 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $64.00 | $8.38 |
| AVG Volume (30 Days) | ★ 12.3K | 3.6K |
| Earning Date | 05-11-2026 | 03-12-2026 |
| Dividend Yield | ★ 1.79% | N/A |
| EPS Growth | ★ 31.88 | N/A |
| EPS | ★ 1.75 | N/A |
| Revenue | ★ $43,950,872.00 | N/A |
| Revenue This Year | $10.30 | N/A |
| Revenue Next Year | $10.00 | $318.52 |
| P/E Ratio | $31.87 | ★ N/A |
| Revenue Growth | ★ 13.46 | N/A |
| 52 Week Low | $24.85 | $3.36 |
| 52 Week High | $62.15 | $5.36 |
| Indicator | ESP | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 49.44 | 34.20 |
| Support Level | $52.83 | $4.04 |
| Resistance Level | $61.58 | $4.07 |
| Average True Range (ATR) | 2.52 | 0.27 |
| MACD | -0.15 | -0.07 |
| Stochastic Oscillator | 53.69 | 0.00 |
Espey Manufacturing & Electronics Corp is a power electronics design and OEM manufacturing company delivering products for military and severe environment applications. Its products include power supplies, power converters, filters, power transformers, magnetic components, power distribution equipment, UPS systems, and antennas. The applications of these products include AC and DC locomotives, shipboard power, shipboard radar, airborne power, ground-based radar, and ground mobile power. Espey services include design and development to specification, build to specifications provided by the customer, build to print, design services, design studies, environmental testing services, metal fabrication, painting services, and development of automatic testing equipment.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.